Brain-derived neurotrophic factor Val66Met genotype and ovarian steroids interactively modulate working memory-related hippocampal function in women: a multimodal neuroimaging study

Mol Psychiatry. 2018 Apr;23(4):1066-1075. doi: 10.1038/mp.2017.72. Epub 2017 Apr 18.

Abstract

Preclinical evidence suggests that the actions of ovarian steroid hormones and brain-derived neurotrophic factor (BDNF) are highly convergent on brain function. Studies in humanized mice document an interaction between estrus cycle-related changes in estradiol secretion and BDNF Val66Met genotype on measures of hippocampal function and anxiety-like behavior. We believe our multimodal imaging data provide the first demonstration in women that the effects of the BDNF Val/Met polymorphism on hippocampal function are selectively modulated by estradiol. In a 6-month pharmacological hormone manipulation protocol, healthy, regularly menstruating, asymptomatic women completed positron emission tomography (PET) and functional magnetic resonance imaging (fMRI) scans while performing the n-back working memory task during three hormone conditions: ovarian suppression induced by the gonadotropin-releasing hormone agonist, leuprolide acetate; leuprolide plus estradiol; and leuprolide plus progesterone. For each of the three hormone conditions, a discovery data set was obtained with oxygen-15 water regional cerebral blood flow PET in 39 healthy women genotyped for BDNF Val66Met, and a confirmatory data set was obtained with fMRI in 27 women. Our results, in close agreement across the two imaging platforms, demonstrate an ovarian hormone-by-BDNF interaction on working memory-related hippocampal function (PET: F2,37=9.11, P=0.00026 uncorrected, P=0.05, familywise error corrected with small volume correction; fMRI: F2,25=5.43, P=0.01, uncorrected) that reflects differential hippocampal recruitment in Met carriers but only in the presence of estradiol. These findings have clinical relevance for understanding the neurobiological basis of individual differences in the cognitive and behavioral effects of ovarian steroids in women, and may provide a neurogenetic framework for understanding neuropsychiatric disorders related to reproductive hormones as well as illnesses with sex differences in disease expression and course.

Trial registration: ClinicalTrials.gov NCT00004571 NCT00001258 NCT00001322.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural

MeSH terms

  • Adult
  • Brain-Derived Neurotrophic Factor / genetics*
  • Brain-Derived Neurotrophic Factor / metabolism*
  • Cerebrovascular Circulation
  • Double-Blind Method
  • Estradiol / administration & dosage
  • Estradiol / blood
  • Female
  • Gonadal Steroid Hormones / metabolism*
  • Hippocampus / diagnostic imaging
  • Hippocampus / metabolism*
  • Humans
  • Leuprolide / pharmacology
  • Magnetic Resonance Imaging
  • Memory, Short-Term / physiology*
  • Methionine / genetics
  • Middle Aged
  • Multimodal Imaging / methods
  • Neuroimaging / methods
  • Neuropsychological Tests
  • Ovary / metabolism
  • Polymorphism, Single Nucleotide
  • Positron-Emission Tomography
  • Progesterone / administration & dosage
  • Progesterone / blood
  • Random Allocation
  • Suppositories
  • Valine / genetics

Substances

  • Brain-Derived Neurotrophic Factor
  • Gonadal Steroid Hormones
  • Suppositories
  • Progesterone
  • Estradiol
  • BDNF protein, human
  • Methionine
  • Leuprolide
  • Valine

Associated data

  • ClinicalTrials.gov/NCT00004571
  • ClinicalTrials.gov/NCT00001258
  • ClinicalTrials.gov/NCT00001322